Drug Trial Radar · NCT06952634
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 29, 2025
Primary completion
Mar 24, 2026
Study completion Mar 24, 2026
Sponsor
- Lead sponsor
- Alumis IncIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Conditions
- Hepatic Impairment
Interventions
envudeucitinibDrug
Single oral dose of ESK-001 in participants from all cohorts
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: 48 hours
- Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]Time frame: 48 hours
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]Time frame: 48 hours
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Orange County Research Center
Lake Forest, California
Panax Clinical Research
Miami Lakes, Florida
Orlando Clinical Research Center
Orlando, Florida
Alliance for Multispecialty Research
Knoxville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.